Company: INMB
Filing Date: 2025-06-16
Form Type: S-8
Source: 0001213900-25-054427
Chunk: 7

Company: Inmune Bio, Inc.
Filing Date: 2025-06-16
Form: S-8
Chunk 7
---
. CORDStrom
for the treatment of children with RDEB has completed a pivotal blinded randomized cross-over trial. The data will be submitted for a
marketing authorization by filing a biologics license application with the FDA which is anticipated in the first half of 2026. Afterwards,
the company intends to file a marketing authorization application in the United Kingdom and EU.

Corporate Information

Our principal executive offices are located at 225 NE Mizner Blvd.,
Suite 640, Boca Raton, Florida 33432. Our telephone number is (561) 710-0512. We maintain an Internet website at www.inmunebio.com. The
information contained on, connected to or that can be accessed via our website is not part of this reoffer prospectus and should not be
relied upon in connection with making any decision with respect to an investment in our securities. We are required to file annual, quarterly
and current reports, proxy statements and other information with the SEC. You may obtain any of the documents filed by us with the SEC
at no cost from the SEC’s website at http://www.sec.gov.

About This Offering

This offering relates to the resale by the selling stockholders of
up to 3,065,332 shares of common stock issued or issuable upon exercise of options issued pursuant to grants made pursuant to our 2021
Plan. If, subsequent to the date of this reoffer prospectus, we grant additional shares of common stock to the selling stockholders or
to other affiliates under the 2021 Plan, we may supplement this reoffer prospectus to reflect such additional shares to the selling stockholders
and/or the names of such affiliates and the number of shares to be reoffered by them under the 2021 Plan. Subject to the satisfaction
of any conditions to vesting of the shares of common stock offered hereby pursuant to the terms of the relevant award agreements, the
selling stockholders may from time to time sell, transfer or otherwise dispose of any or all of the shares of common stock covered by
this reoffer prospectus through underwriters or dealers, directly to purchasers (or a single purchaser) or through broker-dealers or agents.
We will not receive any proceeds from the sale of common stock by the selling stockholders. The selling stockholders will bear all sales
commissions and similar expenses. We will bear all expenses of registration incurred in connection with this offering, including any other
expenses incurred by us in connection with the registration and